Ziff Brothers Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Ziff Brothers Investments’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$12M	Buy	129,500 +15,000	+13%	+$1.41M	4.49%	13
2016 Q2	$8.91M	Hold	114,500	–	–	2.22%	13
2016 Q1	$9.44M	Buy	114,500 +20,000	+21%	+$1.63M	2.21%	11
2015 Q4	$9.9M	Buy	94,500 +44,500	+89%	+$4.65M	2.74%	11
2015 Q3	$5.27M	Buy	+50,000	New	+$6.68M	1.87%	11

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ziff Brothers Investments's BMRN Position: Q3 2016 in Review

Ziff Brothers Investments increased its BioMarin Pharmaceuticals (BMRN) stake by 13% in Q3 2016, buying an estimated $1.41M and bringing the position to 129,500 shares worth $12M. The position accounts for 4.49% of the portfolio, ranked #13.

Ziff Brothers Investments first reported a position in BMRN in Q3 2015 and has held it in 5 quarters since. 423 funds tracked by Wall St. Rank hold BMRN as of Q3 2016.

Ziff Brothers Investments held 129,500 shares of BioMarin Pharmaceuticals worth $12M as of Q3 2016.
Ziff Brothers Investments bought 15,000 BioMarin Pharmaceuticals shares in Q3 2016, an estimated $1.41M.
BioMarin Pharmaceuticals made up 4.49% of Ziff Brothers Investments's portfolio in Q3 2016, its #13 holding.
Ziff Brothers Investments first reported a position in BioMarin Pharmaceuticals in Q3 2015 and has held it in 5 quarters since.
423 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2016.

Based on Ziff Brothers Investments's 13F filing for Q3 2016, filed 14 Nov 2016.